Urimar-t Caps Capsule
NDC Package 28595-224-60

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Urimar-t Caps (methenamine, sodium phosphate, monobasic, monohydrate, phenyl salicylate, methylene blue, and hyoscyamine sulfate) capsules is uRIMAR-T™ CAPS is indicated for the treatment of symptoms of irritative voiding. This formulation utilizes a capsule delivery system. Marketed by Allegis Pharmaceuticals, Llc, this product is identified by NDC 28595-224.

Identification & Billing

NDC Package Code
28595-224-60
Package Description
60 CAPSULE in 1 BOTTLE
Product Code
28595-224
11-Digit Billing Format
28595022460
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
60 EA
RxNorm Crosswalk
  • RxCUI: 2637557 - hyoscyamine sulfate 0.12 MG / methenamine 120 MG / methylene blue 10.8 MG / phenyl salicylate 36.2 MG / sodium phosphate, monobasic 40.8 MG Oral Capsule
  • RxCUI: 2640308 - Urimar-T Oral Capsule, reformulated Oct 2013
  • RxCUI: 2640308 - hyoscyamine sulfate 0.12 MG / methenamine 120 MG / methylene blue 10.8 MG / phenyl salicylate 36.2 MG / sodium phosphate, monobasic 40.8 MG Oral Capsule [Urimar Reformulated Oct 2013]
  • RxCUI: 2640308 - Urimar-T (hyoscyamine sulfate 0.12 MG / methenamine 120 MG / methylene blue 10.8 MG / phenyl salicylate 36.2 MG / sodium phosphate, monobasic 40.8 MG) Oral Capsule, reformulated Oct 2013

Clinical Specifications

Proprietary Name
Urimar-t Caps
Non-Proprietary Name
Methenamine, Sodium Phosphate, Monobasic, Monohydrate, Phenyl Salicylate, Methylene Blue, And Hyoscyamine Sulfate
Substance Name
Hyoscyamine Sulfate; Methenamine; Methylene Blue; Phenyl Salicylate; Sodium Phosphate, Monobasic, Monohydrate
Dosage Form
Capsule - A solid oral dosage form consisting of a shell and a filling. The shell is composed of a single sealed enclosure, or two halves that fit together and which are sometimes sealed with a band. Capsule shells may be made from gelatin, starch, or cellulose, or other suitable materials, may be soft or hard, and are filled with solid or liquid ingredients that can be poured or squeezed.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Pharmacologic Class
Usage Information
URIMAR-T™ CAPS is indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures.

Regulatory & Marketing

Labeler Name
Allegis Pharmaceuticals, Llc
Product Type
Human Prescription Drug
Marketing Category
UNAPPROVED DRUG OTHER - An unapproved drug product in a marketing category that is not reflected on a particular list.
Start Marketing Date
06-28-2023
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 28595-224-60 identifies a specific commercial package of 60 capsule in 1 bottle of Urimar-t Caps, a human prescription drug labeled by Allegis Pharmaceuticals, Llc. This product is billed for "EA" each discreet unit and contains an estimated amount of 60 billable units per package. This capsule is formulated for oral use and contains hyoscyamine sulfate; methenamine; methylene blue; phenyl salicylate; sodium phosphate, monobasic, monohydrate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Allegis Pharmaceuticals, Llc on June 28, 2023. The current certification is valid through December 31, 2026.

How is this Allegis Pharmaceuticals, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 28595022460. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 60 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
28595-224-60
11-Digit CMS (5-4-2)
28595-0224-60

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.